(VIANEWS) – Ramco (RPT), Gilead Sciences (GILD), Stryker Corp (SYK) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up to now. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Ramco (RPT)
637.5% Payout Ratio
RPT Realty owns and operates a national portfolio of open-air shopping destinations principally located in top U.S. markets. The Company's shopping centers offer diverse, locally-curated consumer experiences that reflect the lifestyles of their surrounding communities and meet the modern expectations of the Company's retail partners. The Company is a fully integrated and self-administered REIT publicly traded on the New York Stock Exchange (the Â“NYSEÂ”). The common shares of the Company, par value $0.01 per share (the Â“common sharesÂ”) are listed and traded on the NYSE under the ticker symbol Â“RPTÂ”. As of June 30, 2020, our property portfolio consisted of 49 shopping centers (including five shopping centers owned through a joint venture) representing 11.9 million square feet of gross leasable area. As of June 30, 2020, the Company's pro-rata share of the aggregate portfolio was 93.6% leased.
Earnings Per Share
As for profitability, Ramco has a trailing twelve months EPS of $0.08.
Ramco has a trailing twelve months price to earnings ratio of 139.75. Meaning,
the purchaser of the share is investing $139.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.7%.
Year-on-year quarterly revenue growth grew by 0.5%, now sitting on 223.62M for the twelve trailing months.
Ramco’s sales growth is negative 1.9% for the present quarter and 0.5% for the next.
Morningstar, Inc. has stated that the next dividend payment will be Dec 18, 2022. The forward dividend rate for 2020 is 0.52, and the forward dividend yield of 4.7%.
Growth Estimates Quarters
For the current quarter, the company expects a 25% increase in growth and for the next quarter a decline of 160%.
88.07% Payout Ratio
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Earnings Per Share
As for profitability, Gilead Sciences has a trailing twelve months EPS of $0.24.
Gilead Sciences has a trailing twelve months price to earnings ratio of 355. Meaning,
the purchaser of the share is investing $355 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.58%.
Gilead Sciences sales growth was negative 12.4% in the most recent quarter, and negative 5.7% in the following.
50% Payout Ratio
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Earnings Per Share
As for profitability, Stryker Corp has a trailing twelve months EPS of $3.69.
Stryker Corp has a trailing twelve months price to earnings ratio of 61.51. Meaning,
the purchaser of the share is investing $61.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.1%.
Yearly Top and Bottom Value
Stryker Corp’s stock is valued at $226.98 at 01:24 EST, way below its 52-week high of $280.43 and way higher than its 52-week low of $188.84.
Stryker Corp’s sales growth is 7.2% for the ongoing quarter and 7.3% for the next.
Stryker Corp’s worth is above its 50-day moving average of $215.99 and under its 200-day moving average of $228.43.
42.82% Payout Ratio
Sonoco Products Company manufactures and sells industrial and consumer packaging products in North and South America, Europe, Australia, and Asia. The company operates through four segments: Consumer Packaging, Display and Packaging, Paper and Industrial Converted Products, and Protective Solutions. The Consumer Packaging segment provides paper and thermoformed plastic round and shaped rigid containers and trays; extruded and injection-molded plastic products; printed flexible packaging products; brand artwork management; and metal and peelable membrane ends and closures. The Display and Packaging segment offers temporary and semi-permanent point-of-purchase displays; supply chain management services comprising contract packing, fulfillment, and scalable service centers; retail packaging, including printed backer cards, thermoformed blisters, and heat sealing equipment; and paper amenities, such as coasters and glass covers. The Paper and Industrial Converted Products segment provides paperboard tubes, cones, and cores; fiber-based construction tubes; wooden, metal, and composite wire and cable reels and spools; and recycled paperboard, corrugating medium, recovered paper, and material recycling services. The Protective Solutions segment provides custom-engineered, paperboard-based, and molded foam protective packaging and components; and temperature-assured packaging products. The company sells its products in various markets, which include paper, textile, film, food, chemical, packaging, construction, and wire and cable. Sonoco Products Company was founded in 1899 and is headquartered in Hartsville, South Carolina.
Earnings per Share
Sonoco Products Company’s trailing 12 months profit per share is $4.39.
Sonoco Products Company’s trailing 12 months earnings to price ratio is 13.91. The purchaser of the shares is therefore investing $13.91 per dollar in annual earnings.
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 23.06%.
Sonoco Products Company’s current reported volume is 477834, which is approximately 11.07% less than its average volume (5537368).
Earnings before Interest, Taxes and Depreciation
Sonoco Products Company has an EBITDA of 1.29.
38.17% Payout Ratio
Walgreens Boots Alliance, Inc. operates as an integrated healthcare, pharmacy, and retailer in the United States (U.S.), the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides health and wellness, and specialty and home delivery pharmacy services. As of August 31, 2022, this segment operated 8,886 retail stores under the Walgreens and Duane Reade brands in the United States; and 3 specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2022, this segment operated 3,989 retail stores under the Boots, Benavides, and Ahumada brands in the United Kingdom, Thailand, the Republic of Ireland, and Chile; and 543 optical practices, including 160 on a franchise basis. The U.S. Healthcare segment provides value-based primary care services; post-acute and home care management services; and clinical healthcare services. It also operates as a specialty pharmacy integrator and accelerator for hospitals. As of August 31, 2022, this segment operated 334 VillageMD clinics, including 146 co-located clinics, 124 standalone clinics, and 64 affiliate clinics. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
Earnings per Share
Walgreens Boots’ trailing 12 month EPS is $-0.71 in terms of profitability
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was 14.9%.
Walgreens Boots is worth more than its $50.00 moving average over 50 days and its $40.64 moving average over 200 days.
6. Intel (INTC)
30.58% Payout Ratio
Intel Corporation is engaged in designing, manufacturing, and selling computer products and technology worldwide. CCG, DCG and IOTG are the company’s segments. The company offers platform products such as chipsets and central processing units, system-on chip and multichip package, and other products that are non-platform, like accelerators and boards, systems and connectivity products, graphics and memory. It also offers high-performance computing solutions to targeted verticals as well embedded applications in retail, healthcare, and industrial markets. The company also has solutions for autonomous and assisted driving that include compute platforms, active sensors, machine learning-based sensing and mapping, localization, driving policy and computer vision. It also offers cloud service providers, government agencies, communications service providers and other related products that optimize workloads. It serves original equipment and original design producers, as well as cloud service providers. Intel Corporation and MILA have a strategic partnership to jointly develop and use artificial intelligence techniques for improving the search for drugs. It was founded in 1968, and its headquarters are in Santa Clara (California).
Earnings Per Share
As for profitability, Intel has a trailing twelve months EPS of $4.46.
Intel has a trailing twelve months price to earnings ratio of 6.44. Meaning,
the purchaser of the share is investing $6.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.5%.
Previous days news about Intel (INTC)
- According to VentureBeat on Saturday, 26 November, "Tech giants like Google, IBM, Microsoft and Intel also made news this week for the progress they’re making in quantum computing. "